Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) combined with neoadjuvant chemotherapy have improved pathological complete response (pCR) rates in early-stage triple-negative breast cancer (TNBC), yet nearly half of patients fail to achieve a durable response, and primary or acquired immunotherapy resistance remains a major unmet clinical need. Accumulating evidence indicates that dynamic remodelling of the tumour microenvironment (TME) is a central determinant of variable immunotherapy responsiveness. However, existing reviews focused on early-stage TNBC largely centre on immunotherapy regimens themselves, and a systematic synthesis of TME remodelling mechanisms and mechanism-driven combination strategies specifically tailored to the early-stage setting remains lacking. This review systematically dissects the biological mechanisms underpinning TME remodelling in early-stage TNBC, synthesises rational TME-targeted combination immunotherapy strategies, and summarises advances in TME-associated biomarkers for patient stratification. We first outline the defining immunological, stromal, vascular and metabolic features of the early-stage TNBC TME, highlighting key differences from advanced/metastatic disease that underpin the greater immunotherapy sensitivity of early-stage tumours. We then dissect the interconnected regulatory mechanisms driving progressive TME remodelling, focusing on cancer-associated fibroblast (CAF) reprogramming and stromal barrier formation, vascular dysregulation and impaired immune infiltration, and tumour-immune crosstalk driving early immune escape. Building on this mechanistic framework, we evaluate three major classes of TME-remodelling combination strategies—stromal-targeted therapy, vascular normalisation and metabolic intervention—each combined with ICIs—summarising preclinical rationale, early clinical evidence and key limitations. We further review tissue-based, liquid biopsy and imaging biomarkers of TME state for predicting immunotherapy response, and discuss ongoing challenges to clinical implementation. Overall, this review establishes TME remodelling as a critical modulator of immunotherapy outcome in early-stage TNBC and provides a mechanistic framework to inform the design of tailored combination regimens and precision patient stratification, aligning with the core priority of mechanism-driven TME remodelling for early-stage cancer immunotherapy and aiming to expand the population of patients deriving durable benefit from early-stage cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: